Literature DB >> 18485050

Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey.

Laurent Sailler, Camille Attane, Fleur Michenot, Jean-Marie Canonge, Lionel Rostaing, Elizabeth Arlet-Suau, Philippe Arlet, François Launay, Jean-Louis Montastruc, Maryse Lapeyre-Mestre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18485050      PMCID： PMC2492921          DOI： 10.1111/j.1365-2125.2008.03193.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.

Authors:  Frances E Lund; Melissa Hollifield; Kevin Schuer; J Louise Lines; Troy D Randall; Beth A Garvy
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

3.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Authors:  J-E Gottenberg; L Guillevin; O Lambotte; B Combe; Y Allanore; A Cantagrel; C Larroche; M Soubrier; L Bouillet; M Dougados; O Fain; D Farge; X Kyndt; O Lortholary; C Masson; B Moura; P Remy; T Thomas; D Wendling; J-M Anaya; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2004-11-18       Impact factor: 19.103

4.  Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.

Authors:  Chiara Cattaneo; Pierangelo Spedini; Salvatore Casari; Alessandro Re; Alessandra Tucci; Erika Borlenghi; Marco Ungari; Giulia Ruggeri; Giuseppe Rossi
Journal:  Leuk Lymphoma       Date:  2006-06

5.  Immune status and risk for infection in patients receiving chronic immunosuppressive therapy.

Authors:  Thomas Glück; Bernhard Kiefmann; Mathias Grohmann; Werner Falk; Rainer H Straub; Jürgen Schölmerich
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

6.  Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.

Authors:  Edward Keystone; Roy Fleischmann; Paul Emery; Daniel E Furst; Ronald van Vollenhoven; Joan Bathon; Maxime Dougados; Andrew Baldassare; Gianfranco Ferraccioli; Andrew Chubick; James Udell; Matthew W Cravets; Sunil Agarwal; Simon Cooper; Fabio Magrini
Journal:  Arthritis Rheum       Date:  2007-12

7.  Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.

Authors:  Stephanie Kruetzmann; M Manuela Rosado; Holger Weber; Ulrich Germing; Olivier Tournilhac; Hans-Hartmut Peter; Reinhard Berner; Anke Peters; Thomas Boehm; Alessandro Plebani; Isabella Quinti; Rita Carsetti
Journal:  J Exp Med       Date:  2003-04-07       Impact factor: 14.307
  7 in total
  2 in total

1.  Chronic disease: when in doubt, consider accrual into a randomized controlled trial (RCT).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-08       Impact factor: 4.335

2.  CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients.

Authors:  Emilio Besada; Johannes C Nossent
Journal:  PeerJ       Date:  2016-09-20       Impact factor: 2.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.